
Novo Nordisk Secures U.S. Approval for Awiqli, the First Once-Weekly Basal Insulin for Adults with Type 2 Diabetes
Novo Nordisk Secures U.S. Approval for Awiqli, the First Once-Weekly Basal Insulin for Adults with Type 2 Diabetes Novo Nordisk today announced that the US Food and Drug Administration (FDA)…












